---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: ASPIRE"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: ASPIRE. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 24 evidence topics quoted from 15 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence/aspire"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: ASPIRE

<a id="heading-3.1.2"></a>

## 3.1.2 ASPIRE

<a id="heading-3.1.2.1"></a>

### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

#### Registry objective and official title

> “The primary objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of a single intrathecal (IT) dose of TSHA-102 in pediatric females with typical Rett syndrome.”
> “ASPIRE Study: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Administration of TSHA-102, an AAV9-Delivered Gene Therapy, for the Treatment of Pediatric Females Aged >2 to <4 Years With Rett Syndrome”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.1-2"></a>

#### Regulatory purpose: safety data to support a label for patients aged 2 years and older

> “ASPIRE is designed to support a planned BLA submission to enable broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome.”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="heading-3.1.2.2"></a>

### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

#### Registry record: dates, status, and sites

| Field | Quoted record |
| --- | --- |
| Protocol number | “TSHA-102-CL-201” |
| Study start | “2026-05-08” |
| Primary completion (estimated) | “2031-06” |
| Overall status | “Active, not recruiting” |
| Site | “University of Alabama at Birmingham” |
| Site | “Rush University Medical Center” |
| Site | “Boston Children's Hospital” |

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.2-2"></a>

#### FDA alignment and clearance to initiate

> “In January 2026, Taysha announced written alignment with the U.S. Food and Drug Administration (FDA) on the ASPIRE safety-focused trial and the data for inclusion in the planned BLA submission to enable broad labeling of TSHA-102 for patients aged ≥2 years with Rett syndrome. Subsequently, the Company received FDA clearance to initiate the ASPIRE trial.”

Source: [Taysha Gene Therapies full-year 2025 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409dex991.htm)

<a id="topic-3.1.2.2-3"></a>

#### Enrollment across multiple sites and dosing timeline

> “Further advanced dosing in the REVEAL pivotal trial, with enrollment in the ASPIRE trial ongoing across multiple sites; on track to complete dosing in REVEAL and ASPIRE in Q2 2026”

Source: [Taysha Gene Therapies first quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526207633/d99032dex991.htm)

> “ASPIRE trial ongoing with enrollment exceeding the initial target of (N=3); on track to complete dosing of the three patients in Q2 2026 and expect to dose one additional patient in July 2026, further strengthening potential BLA submission for TSHA-102”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="heading-3.1.2.3"></a>

### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

#### Single-group, open-label phase 3 design with blinded central raters

> “ASPIRE is an open-label study designed to evaluate the safety, tolerability and preliminary efficacy of TSHA-102 in 3 pediatric females aged 2 to less than 4 years old with typical Rett syndrome.”
> “The study comprises a screening period, TSHA-102 administration, a primary safety analysis period through 25 weeks post TSHA-102 administration, and an extended follow-up observation period through 5 years post TSHA-102 administration.”
> “Blinded central raters”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.3-2"></a>

#### Extrapolation design: efficacy from REVEAL pivotal, safety from ASPIRE

> “In close collaboration with the FDA we designed the TSHA-102 pivotal program so that efficacy data from the REVEAL pivotal trial in patients aged 6 to <22 years who have reached developmental plateau can be used to represent patients aged 2 to <6 years, while safety data in younger children are generated through the separate ASPIRE trial to support the potential for a broad label for TSHA-102.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="topic-3.1.2.3-3"></a>

#### Pre-developmental plateau population

> “Pre-developmental Plateau Population (females 2 to <4 years)”
> “Evaluate safety and preliminary efficacy; efficacy data to be extrapolated from pivotal trial”

Source: [Taysha Gene Therapies August 2026 corporate presentation (2026)](https://ir.tayshagtx.com/static-files/8da485f7-d48d-42b8-8fa7-388d58d55487)

<a id="topic-3.1.2.3-4"></a>

#### Earlier design: safety in children aged 2 to 6 years

> “Safety of TSHA-102 will be evaluated in females in the pre-developmental plateau population of Rett syndrome (2-6 years), with efficacy data extrapolated from the developmental plateau population”

Source: [Taysha Gene Therapies pivotal trial design announcement (2025)](https://www.sec.gov/Archives/edgar/data/1806310/000119312525129494/d904503dex991.htm)

<a id="heading-3.1.2.4"></a>

### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

#### Inclusion criteria

> “Pediatric females between the ages of 2 and less than 4 years old.”
> “Participant has a clinical diagnosis of classic/typical Rett syndrome with a documented pathogenic mutation of the methyl-CpG-binding protein 2 (MECP2) gene that results in loss of gene function.”
> “Participants must be willing to receive blood or blood products for the treatment of an AE if medically needed.”
> “Participants and parent/caregiver must agree to reside within easy access to the study site prior to the baseline visit and at least 3 months after TSHA-102 treatment.”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.4-2"></a>

#### Exclusion criteria

> “Participant has another neurodevelopmental disorder independent of the MECP2 loss-of-function mutation, or any other genetic syndrome with a progressive course.”
> “Participant has a history of brain injury that causes neurological problems or had grossly abnormal psychomotor development in the first 6 months of life.”
> “Participant has a diagnosis of atypical Rett syndrome or a MECP2 gene mutation that does not cause Rett syndrome.”
> “Participant requires invasive ventilatory support.”
> “Note: Other protocol defined inclusion/exclusion criteria may apply”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="heading-3.1.2.5"></a>

### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

#### Single intrathecal dose adjusted for brain volume

> “Participants receive a single intrathecal (IT) administration of TSHA-102 at 1.0 × 10¹⁵ total vector genomes (vg) adjusted for the participant's brain volume.”
> “TSHA-102 will be administered via lumbar puncture (LP).”
> “TSHA-102 is a recombinant, non-replicating, self-complementary adeno-associated virus serotype 9 (scAAV9) vector encoding for the miniMECP2 gene. TSHA-102 is a one-time intrathecal (IT) administration.”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.5-2"></a>

#### High dose scaled to the lower brain volume of children aged 2 to less than 4 years

> “ASPIRE will enroll three females aged 2 to <4 years with Rett syndrome to evaluate the safety and preliminary efficacy of a single IT administration of high dose TSHA-102 (1x1015 total vg), scaled to account for the lower brain volume in 2 to <4‑year‑olds”

Source: [Taysha Gene Therapies pivotal program progress announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal)

<a id="heading-3.1.2.6"></a>

### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

#### 3.1.2.6.1 Rationale for Using Treatment-emergent Adverse Events as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

##### Primary endpoint: treatment-emergent adverse events through week 25

> “Proportions of participants experiencing any treatment-emergent adverse events (AEs) and serious adverse events (SAEs)”
> “Baseline through Week 25”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-3.1.2.6.1-2"></a>

##### Safety data requirement agreed with the FDA

> “Importantly, we recently reached written alignment with the FDA that our planned BLA submission will include at least three months of safety data from three patients aged two to under four years in the ASPIRE trial to support a broad label for patients aged two years and older with Rett syndrome.”

Source: [Taysha Gene Therapies pivotal program progress announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal)

<a id="topic-3.1.2.6.1-3"></a>

##### Spontaneous milestone gain before 6 years of age limits efficacy assessment

> “Relatively high and variable rates of spontaneous first-time milestone gain were observed in children before 6 years of age, with rates as high as 97% in the youngest participants; most regain occurred within several years after loss, with milestone-specific variation (Figure 3A–C)”
> “Including participants younger than age 6 years may increase spontaneous milestone gain/regain rates and inflate type I error risk if not explicitly accounted for in the analysis framework”

Source: [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

> “Up to 97% likelihood of spontaneous milestone gain before age 6 may create challenges in distinguishing treatment effect from spontaneous improvement”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

<a id="topic-3.1.2.6.1-4"></a>

##### Regulatory framework: pediatric extrapolation and additional safety data

> “The principles underlying the appropriate use of data generated in a reference population(s) to define the scope and extent of efficacy data that needs to be collected in a target population can also apply to the generation of safety data (see section 4.1.7).”
> “Additional consideration as part of the pediatric extrapolation concept should be given to the collection of pediatric safety data in certain situations. Examples include:”
> “When the drug is a new molecular entity for a new class of drugs;”

Source: [ICH E11A guideline (2024)](https://database.ich.org/sites/default/files/ICH_E11A_Guideline_Step4_2024_0821.pdf)

<a id="heading-3.1.2.7"></a>

### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

#### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

##### Planned enrollment of three participants, overenrolled to four

> “Taysha has elected to overenroll the trial to include one additional screened and eligible patient and will now dose a total of four females with Rett syndrome, aged 2 to <4 years, to evaluate the safety and preliminary efficacy of a single IT administration of high dose TSHA-102 (1x1015 total vg), scaled to account for the lower brain volume in 2 to <4-year-olds”

Source: [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm)

<a id="topic-3.1.2.7.1-2"></a>

##### Dosing completed in four participants

> “Taysha completed dosing in the overenrolled ASPIRE trial, with a total of four patients with Rett syndrome, aged 2 to <4 years, dosed with TSHA-102.”

Source: [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm)

<a id="heading-3.1.2.7.2"></a>

#### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

#### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

##### Four participants dosed; enrollment complete

> “A total of four participants were treated with the high dose (1×10¹⁵ total vg) of TSHA-102, scaled to account for the lower brain volume in 2 to <4 year olds. Enrollment for this trial is complete.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

<a id="topic-3.1.2.8.1-2"></a>

##### All participants past the acute post-dosing monitoring period

> “All patients in the REVEAL Phase 1/2 (n=12), pivotal (n=17) and ASPIRE (n=4) trials have cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies with no dose-limiting toxicities observed across all trials.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="heading-3.1.2.8.2"></a>

#### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

##### Age at dosing

> “We have completed dosing of four patients aged 2 to <4 years with Rett syndrome in the overenrolled ASPIRE trial to evaluate the safety and preliminary efficacy of a single intrathecal administration of high dose TSHA-102 (1x1015 total vg), scaled to account for the lower brain volume in 2 to <4-year-olds.”

Source: [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm)

<a id="heading-3.1.2.8.3"></a>

#### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

#### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

#### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

##### Pooled safety across REVEAL Phase 1/2, REVEAL pivotal, and ASPIRE as of November 2026

> “High dose (1x1015 total vector genomes (vg)) and low dose (5.7x1014 total vg) TSHA-102 continue to be generally well tolerated with no severe treatment-related serious adverse events (SAEs) or dose limiting toxicities (DLTs) in all patients treated in the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials (N=33) as of the November 2026 data cutoff.”

Source: [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm)

<a id="heading-3.1.2.9"></a>

### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

#### Summary

- ASPIRE is a multicenter, open-label study in which every participant receives TSHA-102. It dosed 4 participants (3 planned) aged 2 to less than 4 years, and the registry lists 3 sites.
- The registry primary endpoint is the proportion of participants experiencing any treatment-emergent adverse events and serious adverse events from baseline through week 25. The planned BLA is to include a minimum of 3 months of ASPIRE safety data, which is shorter than the 25-week primary safety analysis period and the 5-year follow-up period.
- No ASPIRE-specific safety results have been reported. The available safety statement pools 33 participants across REVEAL Phase 1/2 (12), REVEAL pivotal (17), and ASPIRE (4) and reports the absence of severe treatment-related serious adverse events and dose-limiting toxicities as of the November 2026 data cutoff; it does not report the type or frequency of other adverse events in the 4 ASPIRE participants.
- No efficacy results have been reported. Efficacy in children aged 2 to less than 6 years is to be extrapolated from REVEAL pivotal participants aged 6 to less than 22 years in the developmental plateau population. The natural history analysis reports spontaneous first-time gain of a single milestone as high as 97% before 6 years of age, and states that including younger participants without explicit age accounting could increase background spontaneous gain.
- None of the three trials has dosed children aged 4 to less than 6 years: ASPIRE enrolls children aged 2 to less than 4 years, the 12 REVEAL Part A participants were 6 to 21 years of age at dosing, and REVEAL pivotal enrolls participants aged 6 to less than 22 years.
- The dose is 1.0 × 10¹⁵ total vector genomes adjusted for brain volume; no description of the scaling method or of the doses administered was identified.
- The registry states that other protocol-defined inclusion and exclusion criteria may apply, and no published protocol, statistical analysis plan, or description of analysis sets was identified.
- All information comes from the sponsor's registry record, press releases, and SEC filings and from a natural history analysis. The company's August 2026 corporate presentation describes efficacy data for females aged 2 to less than 4 years as to be extrapolated from the pivotal trial, while the Form 10-K and the third quarter 2026 Form 10-Q describe extrapolation to the 2 to less than 6-year-old population.

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564); [Taysha Gene Therapies third quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456974/d497108dex991.htm); [Taysha Gene Therapies third quarter 2026 Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526456949/tsha-20260930.htm); [Taysha Gene Therapies second quarter 2026 results announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm); [Taysha Gene Therapies REVEAL pivotal dosing completion announcement (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817dex991.htm); [Taysha Gene Therapies pivotal program progress announcement (2026)](https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal); [Taysha Gene Therapies Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115202/tsha-20251231.htm); [Taysha Gene Therapies August 2026 corporate presentation (2026)](https://ir.tayshagtx.com/static-files/8da485f7-d48d-42b8-8fa7-388d58d55487); [Montgomery et al. (2026)](https://tayshagtx.com/wp-content/uploads/The-Developmental-Plateau-in-Rett-Syndrome-New-Insights-from-the-Natural-History-Study-Inform-Novel-Interventional-Study-Designs.pdf)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
